Bibliometric Analysis of Pyrimidine Compounds with Anti-cancer Activity: Research Trends from 2015 to 2023

Cancer remains one of the most pervasive diseases in the world, globally, leading to millions of fatalities annually. Currently, numerous anti-cancer treatments are available to address the various types of cancer. Pyrimidine, a class of heterocyclic nitrogenous compounds, holds substantial promise in anti-cancer drug development due to its structural similarity to the nucleotide base pairs found in DNA and RNA. This work aimed to conduct a bibliometric analysis of studies on pyrimidine compounds with anti-cancer characteristics. Using the Scopus database, we examined literature published between 2015 and 2023, explicitly concentrating on pyrimidine derivatives as potential anti-cancer agents. Data analysis such as network analysis, co-occurrence, and visualization were conducted utilizing VOSviewer 1.6.13. Nine hundred twenty-two papers altogether, including reviews and original research, discussing the anti-cancer activity of pyrimidine compounds were identified within the specified timeframe up to January 10, 2023. Among these, 922 journal articles were selected for further analysis. Results show that Egypt led in research productivity with 267 articles (28.96%), followed by India with 234 articles (25.38%), and China with 163 articles (17.68%). Cairo University in Egypt ranked first in institutional productivity with 9 articles (0.98%), while the journal Bioorganic Chemistry was the most prolific, publishing 62 articles (6.72%) on pyrimidine compounds with anti-cancer activity. The notable increase in publications on the anti-cancer activity of pyrimidine compounds in recent years underscores the significant interest they have garnered from both pharmaceutical and academic researchers. The data presented in this study will serve as a foundational reference for future comparative studies in this area.